Study for renal outcomes with different combination therapies including Telmisartan in patients with type 2 diabetes and hypertension

Study for renal outcomes with different combination therapies including Telmisartan in patients with type 2 diabetes and hypertension - Study for the effect of telmisartan on renal benefits in patients with type 2 diabetes and hypertension

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005865

Enrollment

105

Registered

2011-06-28

Start date

2011-06-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

Telmisartan Telmisartan/ Hydrochlorothiazide Telmisartan/ Amlodipine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)patients with type 2 diabetes using standard dose of ARB, 2) urine albumin excretion ratio 30-300mg/gCr 3)systolic blood pressure 130-160mmHg 4) HbA1c < 8%(JDS), 5) lipid control is well controlled 6) written informed consent

Exclusion criteria

Exclusion criteria: 1) severe hepatic dysfunction, renal dysfunction, heart failure, 2) history of anaphylaxis of Telmisartan, Hydrochlorothiazide or Amlodipine , 3) pregnancy, 4) patients who are inadequate to enter this study due to the other reasons by physician's judgments

Design outcomes

Primary

Measure	Time frame
Change in urine albumin excretion ratio	—

Secondary

Measure	Time frame
1) blood pressure, 2) HbA1c, plasma glucose, 3) uric acid, 4) urine sodium excretion radio	—

Countries

Japan

Contacts

Public ContactHideaki Miyoshi

Hokkaido University Hospital Department of Internal Medicine II

hmiyoshi@med.hokudai.ac.jp011-706-5915

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026